[지배구조 리포트] 오너 3세 승계 준비하는 대웅, 핵심 지표 후퇴

Daewoo Pharmaceutical's corporate governance compliance rate declined to 73.3%, raising shareholder concerns as the company prepares for third-generation succession. Key governance gaps include insufficient audit committee expertise and compromised board independence, with non-independent directors occupying key positions. Addressing these structural weaknesses is critical to build stakeholder confidence during this leadership transition and meet growing global ESG compliance standards.